Drug News

Amoxicillin Scarcity Triggers Shortage of Combination Products

There are reports of a growing scarcity of Amoxicillin which has led to a shortage of amoxicillin combination products like amoxicillin and clavulanate.

According to drugs.com, amoxicillin and clavulanate is a  penicillin antibiotic that fights bacteria in the body. Clavulanate potassium is a beta-lactamase inhibitor that helps prevent certain bacteria from becoming resistant to amoxicillin.

Amoxicillin and clavulanate potassium is used to treat many different infections caused by bacteria, such as pneumonia, ear infections, bronchitis, urinary tract infections, and infections of the skin.

Among three drugmakers, 29 amoxicillin and clavulanate oral presentations are on allocation or back order, according to the American Society of Health-System Pharmacists

London-based Hikma Pharmaceuticals has 10 products on allocation, Switzerland-based Sandoz has 16 on backorder without an estimated resupply date and Israel-based Teva Pharmaceuticals has three on back order with resupply dates between late November and early January. 

Amoxicillin has been in shortage for weeks, and the FDA confirmed the issue in late October. As of Nov. 18, resupply dates have been pushed to be between early December 2022 and August 2023, depending on the company and the product.


Dr. Oche Otorkpa PG Cert, MPH, PhD

Dr. Oche is a seasoned Public Health specialist who holds a post graduate certificate in Pharmacology and Therapeutics, an MPH, and a PhD both from Texila American University. He is a member of the International Society of Substance Use Professionals and a Fellow of the Royal Society for Public Health in the UK. He authored two books: "The Unseen Terrorist," published by AuthorHouse UK, and "The Night Before I Killed Addiction."
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker